Risk Factors and Outcomes of Stenotrophomonas maltophilia Bacteraemia: A Comparison with Bacteraemia Caused by Pseudomonas aeruginosa and Acinetobacter Species

被引:55
作者
Hotta, Go [1 ]
Matsumura, Yasufumi [1 ]
Kato, Karin [1 ]
Nakano, Satoshi [1 ]
Yunoki, Tomoyuki [1 ]
Yamamoto, Masaki [1 ]
Nagao, Miki [1 ]
Ito, Yutaka [2 ]
Takakura, Shunji [1 ]
Ichiyama, Satoshi [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Clin Lab Med, Sakyo Ku, Kyoto, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Resp Med, Sakyo Ku, Kyoto, Japan
来源
PLOS ONE | 2014年 / 9卷 / 11期
关键词
XANTHOMONAS-MALTOPHILIA; TRIMETHOPRIM-SULFAMETHOXAZOLE; ANTIMICROBIAL THERAPY; SURVEILLANCE; MULTICENTER; MORTALITY;
D O I
10.1371/journal.pone.0112208
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Stenotrophomonas maltophilia (SM) is an important nosocomial pathogen that exhibits intrinsic resistance to various antimicrobial agents. However, the risk factors for SM bacteraemia have not been sufficiently evaluated. From January 2005 to September 2012, we retrospectively compared the clinical backgrounds and outcomes of SM bacteraemic patients (SM group) with those of bacteraemic patients due to Pseudomonas aeruginosa (PA group) or Acinetobacter species (AC group). DNA genotyping of the SM isolates using the Diversilab system was performed to investigate the genetic relationships among the isolates. The SM, PA, and AC groups included 54, 167, and 69 patients, respectively. Nine of 17 patients in the SM group receiving trimethoprim-sulfamethoxazole prophylaxis developed SM bacteraemia. Independent risk factors for SM bacteraemia were the use of carbapenems and antipseudomonal cephalosporins and SM isolation within 30 days prior to the onset of bacteraemia. Earlier SM isolation was observed in 32 of 48 patients (66.7%) with SM bacteraemia who underwent clinical microbiological examinations. Of these 32 patients, 15 patients (46.9%) had the same focus of bacteraemia as was found in the previous isolation site. The 30-day all-cause mortality rate among the SM group (33.3%) was higher than that of the PA group (21.5%, p = 0.080) and the AC group (17.3%, p = 0.041). The independent factor that was associated with 30-day mortality was the SOFA score. DNA genotyping of SM isolates and epidemiological data suggested that no outbreak had occurred. SM bacteraemia was associated with high mortality and should be considered in patients with recent use of broad-spectrum antibiotics or in patients with recent isolation of the organism.
引用
收藏
页数:9
相关论文
共 38 条
[1]   Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients:: A case-control study [J].
Apisarnthanarak, A ;
Mayfield, JL ;
Garison, T ;
McLendon, PM ;
DiPersio, JF ;
Fraser, VJ ;
Polish, LB .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2003, 24 (04) :269-274
[2]   Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009 [J].
Araoka, H. ;
Baba, M. ;
Yoneyama, A. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2010, 29 (05) :605-608
[3]   The role of surveillance cultures in the prediction of susceptibility patterns of Gram-negative bacilli in the intensive care unit [J].
Baba, H. ;
Nimmo, G. R. ;
Allworth, A. M. ;
Boots, R. J. ;
Hayashi, Y. ;
Lipman, J. ;
Paterson, D. L. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2011, 30 (06) :739-744
[4]   Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients [J].
Boktour, M ;
Hanna, H ;
Ansari, S ;
Bahna, B ;
Hachem, R ;
Tarrand, J ;
Rolston, K ;
Safdar, A ;
Raad, I .
CANCER, 2006, 106 (09) :1967-1973
[5]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[6]   Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen [J].
Brooke, Joanna S. .
CLINICAL MICROBIOLOGY REVIEWS, 2012, 25 (01) :2-41
[7]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[8]   Can Levofloxacin Be a Useful Alternative to Trimethoprim- Sulfamethoxazole for Treating Stenotrophomonas maltophilia Bacteremia? [J].
Cho, Sun Young ;
Kang, Cheol-In ;
Kim, Jungok ;
Ha, Young Eun ;
Chung, Doo Ryeon ;
Lee, Nam Yong ;
Peck, Kyong Ran ;
Song, Jae-Hoon .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (01) :581-583
[9]  
Clinical and Laboratory Standards Institute, 2012, M100S22 CLSI
[10]   Characterization of flagella produced by clinical strains of Stenotrophomonas maltophilia [J].
de Oliveira-Garcia, D ;
Dall'Agnol, M ;
Rosales, M ;
Azzuz, ACGS ;
Martinez, MB ;
Girón, JA .
EMERGING INFECTIOUS DISEASES, 2002, 8 (09) :918-923